Educational only. Compounded medications are not FDA-approved. A prescription is required and is not guaranteed. YourHealthRx does not prescribe, dispense, or store patient health information. Clinical services are provided by independent licensed providers. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
Most people regain some of the weight they lost if they stop a GLP-1. That is not a character test. It is what the withdrawal trials show when the medicine is taken away and nothing else is put in its place.
People ask this before they start, and again when side effects, cost, or a plateau shows up. The honest answer is the same in both moments: stopping is a clinical decision, not a checkout setting.
Bottom line: Regain after stopping is common in the published data. Staying on, pausing, or stopping belongs with a licensed clinician.
YourHealthRx framing: education first, then eligibility if you want a clinician to review whether a GLP-1 pathway, including a plan for follow-up, is appropriate.
Do you regain weight after stopping a GLP-1?
Often, yes. The two clearest datasets are withdrawal studies, not anecdotes.
In the STEP 1 extension, 327 people who had finished 68 weeks of once-weekly semaglutide 2.4 mg (or placebo) were followed for another year off treatment. The semaglutide group had lost a mean 17.3% of body weight by week 68. After withdrawal they regained a mean 11.6 percentage points by week 120, a net 5.6% below their original baseline. That is about two-thirds of the prior loss coming back. Most of the cardiometabolic improvements seen on treatment also moved back toward baseline (Wilding et al., 2022).
SURMOUNT-4 asked a related question with tirzepatide. After 36 weeks of open-label tirzepatide, 670 adults had lost a mean 20.9% of body weight. They were then randomized to continue tirzepatide or switch to placebo for 52 weeks. From that point, people who stayed on tirzepatide lost another 5.5%. People switched to placebo regained 14.0%. At week 88, 89.5% of those still on tirzepatide had kept at least 80% of the weight they lost in the lead-in, compared with 16.6% on placebo (Aronne et al., JAMA 2024).
Those numbers describe trial averages in defined groups on studied products. They are not a promise of what will happen to you, on a compounded formulation or on a brand pen. They are also not a reason to treat regain as a personal failure.
Why does weight come back?
GLP-1 medicines act on appetite signaling, gastric emptying, and glucose handling while you take them. When the signal stops, the biology that was there before is still there. Hunger can return. The set of habits that existed around food does not automatically stay locked in.
Obesity is treated as a chronic condition in this literature. The STEP 1 extension authors wrote that the findings “confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.” SURMOUNT-4 reached the same kind of conclusion for continued tirzepatide versus withdrawal.
That is a medical frame, not a sales line. Some people stop because of pregnancy plans, gastrointestinal effects, cost, or because a clinician decides the medicine is no longer a fit. Those are real reasons. They still belong in a visit, not in a sudden halt.
Should you stay on a GLP-1 long term?
There is no single correct duration. Labels, trial lengths, and real life are different clocks.
The large weight studies ran for a little over a year. SELECT looked at cardiovascular events with continued weekly semaglutide in a defined high-risk group. Withdrawal studies then showed what happens when the drug is removed. Together they support this: if the goal is keeping the change you got on treatment, staying on is the pattern with the stronger data. If the goal is a short course, expect the possibility of regain and plan for it with a clinician.
Staying on is not the same as staying at the same dose, the same form, or the same pharmacy product. Oral dissolving tablets and injections are different routines. Switching, pausing, or stopping is not something to improvise from a search result.
Cost is part of the long-term conversation. YourHealthRx currently lists compounded semaglutide injectable from $140/mo, semaglutide ODT from $170/mo, tirzepatide ODT from $180/mo, and tirzepatide injectable from $190/mo, with a listed rate lock that ends September 15. Those are “as low as” listed prices. They are not a reason to start, and they are not a reason to stay. A prescription is not guaranteed.
Can you stop a GLP-1 on your own?
No. Do not stop, skip, or stretch doses without the prescribing clinician. Gastrointestinal effects, other medicines, pregnancy, gallbladder symptoms, and low intake all change the stop plan.
If you are already thinking about stopping, say so in follow-up. A clinician can talk through whether this is a pause, a dose change, a form change, or a true stop, and what to watch in the weeks after.
FAQ
Will I regain all the weight if I stop?
Not necessarily all of it, and not on a fixed timetable. In STEP 1, people still sat about 5.6% below baseline a year after stopping. In SURMOUNT-4, most people who came off tirzepatide did not keep 80% of the lead-in loss. Individual results vary.
Is regain a sign the medicine failed?
No. Withdrawal studies show regain is a common response when the medicine is removed. It is information for the next clinical decision.
Do I have to stay on a GLP-1 forever?
Not as a slogan. Some people stay on because the condition is chronic and the data for maintenance is stronger with continued treatment. Some people stop for medical or practical reasons. That choice is individualized.
Is stopping different on a compounded GLP-1 than on a brand pen?
Stopping is still a clinician decision either way. Compounded products are not FDA-approved as finished medicines. They are not interchangeable with Wegovy, Ozempic, Zepbound, or Mounjaro without medical review.
Informational only. This article is educational and does not constitute medical advice, diagnosis, treatment, or a patient-clinician relationship. Compounded medications are not FDA-approved. A prescription is required and is not guaranteed. YourHealthRx does not prescribe, dispense, or store patient health information. Clinical services are provided by independent licensed providers. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
Sources: STEP 1 extension, Wilding et al., 2022 · SURMOUNT-4, Aronne et al., JAMA 2024